Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

197.68 +9.83 (+5.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,574,914
Open 191.44
Bid (Size) 193.05 (100)
Ask (Size) 203.90 (100)
Prev. Close 187.85
Today's Range 190.66 - 198.18
52wk Range 125.38 - 256.36
Shares Outstanding 139,693,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ... 
Via StockStory
Topics Economy Stocks
News headline image
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗
Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
-13.6%
-13.6%
1 Month
-4.1%
-4.1%
3 Month
-13.5%
-13.5%
6 Month
+14.8%
+14.8%
1 Year
+32.4%
+32.4%

More News

Read More
News headline image
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
Natera Inc. (NASDAQ:NTRA) Crushes Q4 Earnings Estimates with Strong Oncology Growth ↗
Via Chartmill
News headline image
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
From Natera, Inc.
Via Business Wire
News headline image
3 Growth Stocks to Add to Your Roster
Via StockStory
News headline image
3 Market-Beating Stocks to Target This Week
Via StockStory
News headline image
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis
From Natera, Inc.
Via Business Wire
News headline image
3 Healthcare Stocks to Target This Week
Via StockStory
News headline image
Natera (NTRA) Stock Trades Up, Here Is Why
Via StockStory
Topics Economy
News headline image
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
Via The Motley Fool
Topics Lawsuit
News headline image
Why Natera (NTRA) Shares Are Falling Today
Via StockStory
Topics Earnings Economy
News headline image
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
From Natera, Inc.
Via Business Wire
News headline image
Natera (NTRA) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Natera Reports Fourth Quarter and Full Year 2025 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera Earnings: What To Look For From NTRA
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
From Natera, Inc.
Via Business Wire
News headline image
Billionaire Stanley Druckenmiller Is Betting Big on These 2 Stocks ↗
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
From Natera, Inc.
Via Business Wire
News headline image
Natera Submits Signatera™ CDx PMA to FDA
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
From Natera, Inc.
Via Business Wire
News headline image
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
From Natera, Inc.
Via Business Wire
News headline image
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds
Via StockStory
News headline image
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
From Natera, Inc.
Via Business Wire

Frequently Asked Questions

Is Natera, Inc. - Common Stock publicly traded?
Yes, Natera, Inc. - Common Stock is publicly traded.
What exchange does Natera, Inc. - Common Stock trade on?
Natera, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Natera, Inc. - Common Stock?
The ticker symbol for Natera, Inc. - Common Stock is NTRA on the Nasdaq Stock Market
What is the current price of Natera, Inc. - Common Stock?
The current price of Natera, Inc. - Common Stock is 197.68
When was Natera, Inc. - Common Stock last traded?
The last trade of Natera, Inc. - Common Stock was at 03/16/26 04:00 PM ET
What is the market capitalization of Natera, Inc. - Common Stock?
The market capitalization of Natera, Inc. - Common Stock is 27.61B
How many shares of Natera, Inc. - Common Stock are outstanding?
Natera, Inc. - Common Stock has 28B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.